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ABSTRACT The European Respiratory Society (ERS) accepted 4062 abstracts for presentation at the ERS
International Congress in 2020. Although the conference was held virtually, making it possible to replay
presentations, it remains a challenge to keep abreast of all the clinical and scientific advances. Therefore,
this article provides highlights from the General Pneumology Assembly. Selected presentations from
rehabilitation and chronic care, general practice and primary care, and electronic/mobile health (e-health/
m-health) are summarised. The highlights incorporate novel findings from laboratory-based science,
randomised controlled trials and qualitative research together with insights from newly available clinical
guidelines.
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With travel restrictions and social distancing the norm for much of the year due to coronavirus disease
(COVID-19), the European Respiratory Society (ERS) International Congress, held virtually in September
2020, provided a much valued opportunity to come together. As the world’s largest scientific and
educational conference for respiratory medicine, the ERS International Congress provided an excellent
chance to hear the latest developments in research and clinical practice with 4062 abstracts accepted for
presentation. The General Pneumology Assembly is the largest of the 14 Assemblies within the ERS.
Across the four groups within the Assembly, 346 abstracts were presented in 22 sessions. Although the
virtual platform allowed presentations to be replayed, it can be difficult to keep up to date with all of the
scientific and clinical advances on offer. Therefore, in this article we aim to share some of the highlights
arising from the General Pneumology Assembly.
Pulmonary rehabilitation and chronic care
Session: Best abstracts in pulmonary rehabilitation and chronic care
A peer review of abstracts submitted to the ERS Congress in the field of pulmonary rehabilitation and
chronic care led to the selection of the six most innovative and interesting works, presented by their
authors in the traditional session “Best abstracts in pulmonary rehabilitation and chronic care”. Works
selected this year covered key topics, including cellular mechanisms of muscle regeneration, effects of
high-flow oxygen supplementation during exercise in chronic obstructive pulmonary disease (COPD) and
interstitial lung disease, the efficacy of new exercise training strategies for COPD patients, and effects of a
behavioural change intervention on asthma symptoms.
To investigate the cellular basis of reduced efficacy of exercise training in peripheral muscles in COPD
patients, POMIÈS et al. [1] used in vitro electrical pulse stimulation (EPS) of cultured human myotubes from
nine healthy subjects and nine COPD patients. Compared with myotubes from healthy subjects, after a
24-h EPS protocol at 1 Hz and 11.5 V, myotubes from COPD patients appeared atrophied, had reduced
cellular differentiation and regeneration, and showed impaired protein synthesis and oxidative metabolism
adaptation. This in vitro altered response to EPS could reflect impaired regenerative capacities of satellite
cells, accounting for a lack of muscle adaptation capacity and the limited effects of in vivo exercise training
in COPD patients.
In the same research area of muscle repair and regeneration, SANCHO MUÑOZ et al. [2] investigated the role
of the negative regulator myostatin as a possible inhibitor of muscle regeneration in sarcopenic COPD
patients. Compared with control subjects and COPD patients with normal body composition, sarcopenic
COPD patients had a reduction in quadriceps muscle strength, higher myostatin protein levels, and
increased activated satellite cells, hybrid fibres and TUNEL-positive cell counts. Muscle fibre area and
expression of muscle regeneration markers were also lower than in controls. The authors suggested that an
increased expression of myostatin may have interfered with muscle cell proliferation during the
regeneration process in COPD patients with sarcopenia, thus leading to poor muscle growth following
injury and muscle mass loss.
The effects of high-flow nasal cannula (HFNC) for oxygen supplementation during exercise were analysed
in two selected abstracts. Generating high humidified airflow with constant oxygen fraction, HFNC allows
for a decrease in oxygen dilution in the dead space of the airway. Thus, HFNC generates positive pressure,
improves oxygenation, reduces the respiratory rate and contributes to greater comfort in acute respiratory
failure [3]. In a randomised crossover study, SANGUANWONG et al. [4] compared the effects of supplemental
HFNC, oxygen cannula and without oxygen (control group) during exercise in 13 COPD patients with
exercise-induced desaturation. Subjects were assigned to wear HFNC (60 L·min−1, inspiratory oxygen
fraction (FIO2) 0.4), oxygen cannula (6 L·min
−1) or no oxygen supplement during a cycle ergometer
constant work rate exercise test, set at 70% of peak work rate. Endurance exercise time, dyspnoea and time
to desaturation improved with HFNC and oxygen cannula, with no superiority of HFNC compared with
oxygen cannula. ARIZONO et al. [5] assessed the effect of HFNC therapy on exercise capacity in 20 patients
following an exacerbation of interstitial lung disease. This prospective, single-blind, randomised trial
compared the efficacy during exercise of two different concentrations of oxygen for HFNC: high (FIO2
60%, 40 L·min−1) and low (FIO2 25.1±6.7%, 40 L·min
−1) oxygen concentration. During a constant work
rate exercise test (20 W) 9 days after the exacerbation, with high oxygen concentration, HFNC significantly
increased endurance time and minimum oxygen saturation while heart rate and respiratory rate were
decreased compared with low oxygen, suggesting a high concentration of oxygen for HFNC benefits
exercise capacity.
One of the most relevant challenges in pulmonary rehabilitation and chronic care is how to induce a
sustained change in a patient’s lifestyle to maintain the beneficial effects of pulmonary rehabilitation and
improve control of symptoms and quality of life. Because improvement in physical activity levels and sleep
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quality may be related to asthma control in adults, PASSOS et al. [6] conducted a randomised controlled
trial to investigate whether a behavioural change intervention could improve physical activity levels and
sleep quality in moderate to severe asthma patients. The intervention group followed the same usual care
and educational programme of the control group, but with the addition of an 8-week behavioural change
intervention focused on goal setting and positive feedback. All subjects were assessed on sleep quality
(ActiSleep, Pittsburgh and Berlin questionnaires), physical activity levels (ActiGraph GT9X accelerometer),
asthma symptoms (daily diary) and psychosocial symptoms. A significant improvement in the intervention
group was observed in sleep efficiency and latency, depression symptoms, physical activity levels, and the
number of asthma symptom-free days compared with the control group. The authors suggested that
beneficial effects of the behavioural change intervention on asthma control and psychosocial symptoms
were mediated by the increase in physical activity levels and sleep quality.
To increase adherence to pulmonary rehabilitation programmes, alternative approaches to conventional
programmes have been proposed, focusing on group activities and participation in immersive and
engaging social and physical activity. Singing for Lung Health was recently proposed by the British Lung
Foundation as a group activity tailored to people with respiratory disease (particularly those with airflow
obstruction), and focused on improving breath control and posture using songs [7]. Lung choirs have been
shown to improve respiratory control and wellbeing, but the impact on physical capacity was unclear.
KAASGAARD et al. [8] conducted a multicentre randomised controlled trial to evaluate the effectiveness of
singing training in increasing physical capacity compared with usual physical training. Singing training
was as efficacious as physical training in improving physical capacity and superior for improving quality of
life. Although this study confirmed singing training as a promising strategy for physical training, no
differences were found in symptom control or adherence, suggesting the need for further efforts to
standardise the content of singing training to provide evidence-based recommendations.
General practice and primary care
Session: Primary care day and diagnosis and management of airways disease in primary care
The ERS International Congress 2020 offered much for participants interested in primary care respiratory
medicine. Highlights from the primary care day and the diagnosis and management of airways disease in
primary care sessions are presented.
Diagnosis of asthma or COPD can be difficult and has been more challenging during the COVID-19
pandemic. As a heterogenous disease with different phenotypes [9] and no “gold standard” test that can
confirm or refute the diagnosis in every situation, misdiagnosis of asthma is common [10, 11]. Mike
Thomas emphasised the importance of gaining objective evidence for an asthma diagnosis rather than
relying on symptoms alone. In COPD, spirometry is the key diagnostic test [12], but as Miguel Roman
Rodriguez highlighted, there are barriers to confirming the diagnosis, meaning many cases of COPD
remain undiagnosed [13]. COVID-19 has bought new challenges for diagnostic assessment, principally due
to reduced lung physiology services in many countries [14]. Until laboratory-based testing becomes
available again, alternative options might include peak expiratory flow, portable spirometers and exhaled
nitric oxide monitors, and smartphone technologies [14].
In asthma management, overuse of short-acting β2-agonist (SABA) inhalers is associated with poor clinical
outcomes [9], including an increased risk of asthma attacks, emergency department visits [15] and
mortality [16]. In their study of 70 patients who presented to the emergency department with an asthma
attack, BARMPARESSOU et al. [17] identified that most individuals had “mild” asthma and 27% were treated
only with a SABA. To reduce SABA overprescribing in the UK, electronic prescribing alerts were
introduced in general practices. MCKIBBEN et al. [18] found a clear discrepancy between how clinicians,
experts and guidelines defined excessive SABA use. The volume of warnings and other work pressures
meant that SABA alerts were often ignored [18].
One intervention known to reduce emergency department attendances is supported self-management for
asthma [19]. Asthma action plans can be effectively tailored for different cultural groups [19], but the
influence of limited health literacy on self-management needs further exploration. By conducting a
qualitative study of 26 participants recruited from Malaysian primary care, SALIM et al. [20] found poor
understanding of asthma led to limited acceptance of the condition and treatment, resulting in poor
asthma control. Supporting people with limited health literacy to understand their condition was
recommended for developing good self-management [20].
Helping women with asthma during pregnancy was discussed by Vibeke Backer who highlighted guidance
from the ERS/Thoracic Society of Australia and New Zealand task force [21]. In comparison with
nonasthmatic women, women with asthma have on average a longer time to pregnancy and become
pregnant less often [22]. When considering asthma medication use during pregnancy, inhaled therapies,
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oral corticosteroids and most antihistamines were considered to be without serious side-effects [21]. The
main aim should be to prevent exacerbations, as events which lead to lower maternal oxygenation are
more harmful for the (unborn) child than the potential side-effects of medication. Currently, few studies
are available to inform the use of biological therapies during pregnancy; however, monoclonal antibodies
are considered unlikely to cause harm to the fetus and on balance should be continued during pregnancy
if needed to control the mother’s asthma [21].
The remaining talks considered how primary care clinicians can best support individuals with respiratory
disease that often results from, or coexists with, other conditions. Individuals with COPD often have
multiple comorbidities affecting their health and prognosis [12, 23]. Comorbidities in COPD often occur
in clusters, which suggests common risk factors and shared disease processes [24]. Ioanna Tsiligianni
highlighted the International Primary Care Respiratory Group desktop helper for COPD and
multimorbidity, recommending a holistic approach: identifying and treating comorbidities, screening for
coexisting anxiety or depression, and evaluating the indications and possible side-effects of inhaled
therapies [25]. One important comorbidity of COPD which carries a poor prognosis is pulmonary
hypertension [26]. Defined by a mean pulmonary arterial pressure >25 mmHg, pulmonary hypertension
may arise as a complication of many cardiovascular and respiratory diseases, but can be difficult to
identify as right heart failure occurs in the later stages of disease [26]. To achieve a timely diagnosis (and
better clinical outcomes), Anton Vonk Noordegraaf recommended being alert to the primary symptom of
exercise intolerance, especially in younger patients (aged 30–55 years), and instigating further assessment
with N-terminal pro-brain natriuretic peptide, ECG and echocardiography [26].
Despite the restrictions due to COVID-19, the virtual ERS International Congress 2020 provided
opportunities to learn, discuss and share research and experiences from across the world, and connect with
one another, making the primary care sessions this year particularly valuable and stimulating.
m-Health/e-health
Session: Digital technologies in airway diseases
Growing interest of the ERS in digital medicine interventions resulted in an oral presentation session
organised by Group 1.4 (m-Health/e-Health) dedicated to the use of modern technologies in the
management and treatment of airway diseases. In this rapidly changing world, healthcare workers are
facing new challenges: How can we use new technologies to improve our healthcare system? How can we
ensure that technologies are adopted and useable rather than leaving people baffled? At the same time,
respiratory patients are extremely interested in how they can optimally benefit from innovative
technologies. The session “Digital technologies in airway diseases” provided participants with different
solutions to these questions.
Feedback from patients
When dealing with digital technologies, it is always important to put the needs and preferences of patients
first. In this regard, KHUSIAL et al. [27] and METTING and LAHR [28] reported on feedback they gathered from
patients who had tried digital monitoring systems. KHUSIAL et al. [27] organised focus groups for patients
with asthma to explore their attitudes towards m-health applications. Improving disease outcomes, reducing
consultations and improving disease awareness were all identified as potential goals. Ineffectiveness, time
consumption, privacy issues and information overload were the most important perceived barriers.
Interestingly, patients had divergent opinions on the required functions of an m-health system, suggesting
that these systems should be personalised to their individual needs. METTING and LAHR [28] developed a
monitoring system in the Horizon 2020 Connecare study to coordinate care around chronically ill patients.
The system consisted of a dashboard for healthcare providers and an app for patients. The authors
elaborated on the lessons learned from the feedback provided by 46 COPD patients. Most of these patients
highlighted the ease of use of the chat function. In addition, the authors emphasised the importance of
personalisation and including all stakeholders in the development of a monitoring system.
Remote healthcare
Telemonitoring of vital signs and parameters from patients is a well-known way to use digital technologies.
However, telemonitoring could also be used for helping patients at a distance. CUMELLA et al. [29] showed
that a WhatsApp (www.whatsapp.com) service can reach an otherwise unengaged younger audience of
asthma patients. Patients could reach healthcare providers through WhatsApp and, in response, they
received advice, links, video content or infographics from healthcare providers. A post-chat online survey
of 669 patients with asthma showed the service was well perceived and almost two-thirds of the patients
had more confidence in managing their asthma symptoms after using the service. ADEJUMO et al. [30]
performed a randomised controlled pilot study with 36 asthma patients to assess whether feedback about
inhaler use could affect adherence and clinical outcomes. Inhaler use was monitored with an electronic
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monitoring device for both intervention and control groups. Only the intervention group received monthly
feedback and an app showing their day-to-day inhaler use. A trend towards higher adherence for the
intervention group was identified, whereas no changes in clinical outcomes were observed.
Exacerbation prediction
One of the most common goals of digital technologies for patients with chronic airway diseases is the
prediction of exacerbations and the reduction of hospitalisations. JANSON et al. [31] developed a machine
learning model to predict the immediate risk of asthma exacerbations. Data from electronic medical
records and national registries of almost 30000 asthma patients were used to predict whether they would
exacerbate in the next 15 days. The model indicated that the Charlson Comorbidity Index and previous
exacerbations were the main factors influencing the risk of exacerbations in these patients, but was not
sufficiently accurate to be used in clinical practice. Therefore, the authors concluded that supplemental
data (e.g. pollution, pollen count and information from m-health devices) were needed to develop a more
clinically useful tool. The e-health intervention (EmmaCOPD; https://ec.europa.eu/eip/ageing/repository/
emmacopd_en) developed by VAN BUUL et al. [32] managed to reduce the total number of exacerbations
and hospitalisation days among COPD patients. EmmaCOPD consisted of an app to answer symptom
questionnaires and a smartwatch with a step counter. Depending on the answers to the questionnaires, the
29 included patients with COPD were assigned to a green, yellow, orange or red zone. The system
provided patients with the advice to call a healthcare provider when they entered the orange or red zone.
As a result, EmmaCOPD reduced the total number of exacerbations and hospitalisation days, while
additional work for healthcare providers was kept to a minimum.
Overall, the session highlighted the most important cases of digital technologies for patients with airway
diseases from different countries and improved our understanding of how we should build future
healthcare systems.
Concluding remarks
The General Pneumology Assembly of the ERS offers a wide range of clinical and scientific research, as is
evident in this summary. Given the size of the ERS International Congress, it can be hard to keep abreast
of new developments, even using a virtual platform. Therefore, we hope the highlights from the Assembly
summarised in this article will allow readers to keep up to date with the latest research, revisit topics of
interest and provide encouragement to take part in the ERS International Congress in 2021 to be held in
Barcelona.
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